FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, concomitant administration of these combinations should be avoided (see section 4.5).
Danish: Disse kombinationer bør derfor undgås (se pkt.
English: This study was conducted in 889 patients with locally advanced or metastatic NSCLC who did not progress after 4 cycles of platinum-based doublet chemotherapy.
Danish: Dette studie blev gennemført med 889 patienter med lokalt fremskreden eller metastatisk NSCLC, som ikke progredierede efter 4 cyklusser platinbaseret dublet kemoterapi.
English: In the pancreatic cancer study in combination with gemcitabine, the incidence of ILD-like events was 2.5% in the Tarceva plus gemcitabine group versus 0.4% in the placebo plus gemcitabine treated group.
Danish: I pancreascancerstudiet i kombination med gemcitabin var hyppigheden af ILD-lignende hændelser 2,5 % i gruppen med Tarceva plus gemcitabin versus 0,4 % i gruppen behandlet med placebo plus gemcitabin.
English: The effect of Tarceva on overall survival was similar in patients with a baseline performance status (ECOG) of 2-3 (HR = 0.77, 95% CI 0.6-1.0) or 0-1 (HR = 0.73, 95% CI 0.6-0.9), male (HR = 0.76, 95% CI 0.6-0.9) or female patients (HR = 0.80, 95% CI 0.6-1.1), patients < 65 years of age (HR = 0.75, 95% CI 0.6-0.9) or older patients (HR = 0.79, 95% CI 0.6-1.0), patients with one prior regimen (HR = 0.76, 95% CI 0.6-1.0) or more than one prior regimen (HR = 0.75, 95% CI 0.6-1.0), Caucasian (HR = 0.79, 95% CI 0.6-1.0) or Asian patients (HR = 0.61, 95% CI 0.4-1.0), patients with adenocarcinoma (HR = 0.71, 95% CI 0.6-0.9) or squamous cell carcinoma (HR = 0.67, 95% CI 0.5-0.9), but not in patients with other histologies (HR 1.04, 95% CI 0.7-1.5), patients with stage IV disease at diagnosis (HR = 0.92, 95% CI 0.7-1.2) or < stage IV disease at diagnosis (HR = 0.65, 95% CI 0.5-0.8).
Danish: Virkningen af Tarceva på samlet overlevelse var sammenlignelig hos patienter med baseline performance status (ECOG) på 2-3 (HR = 0,77; 95 % konfidensinterval 0,6-1,0) eller 0-1 (HR = 0,73; 95 % konfidensinterval 0,6-0,9), mandlige patienter (HR = 0,76; 95 % konfidensinterval 0,6-0,9) eller kvindelige patienter (HR = 0,80, 95 % konfidensinterval 0,6-1,1), patienter < 65 år (HR = 0,75; 95 % konfidensinterval 0,6-0,9) eller ældre patienter (HR = 0,79; 95 % konfidensinterval 0,6-1,0), patienter med ét tidligere regime (HR = 0,76; 95 % konfidensinterval 0,6-1,0) eller mere end ét tidligere regime (HR = 0,75; 95 % konfidensinterval 0,6-1,0), kaukasiere (HR = 0,79; 95 % konfidensinterval 0,6-1,0) eller asiatiske patienter (HR = 0,61; 95 % konfidensinterval 0,4-1,0), patienter med adenokarcinom (HR = 0,71; 95 % konfidensinterval 0,6-0,9) eller planocellulært karcinom (HR = 0,67; 95 % konfidensinterval 0,5-0,9), men ikke hos patienter med anden histologi (HR 1,04; 95 %
English: Erlotinib increases platinum concentrations.
Danish: Erlotinib øger koncentrationen af platin.
English: • if you are taking other medicines that may increase or decrease the amount of erlotinib in your blood or influence its effect (for example antifungals like ketoconazole, protease inhibitors, erythromycin, clarithromycin, phenytoin, carbamazepine, barbiturates, rifampicin, ciprofloxacin, omeprazole, ranitidine, St. John's Wort or proteasome inhibitors), talk to your doctor.
Danish: • hvis du tager andre lægemidler, som kan øge eller nedsætte mængden af erlotinib i dit blod eller påvirke effekten af erlotinib (f.eks. svampemidler som ketoconazol, proteasehæmmere, erytromycin, claritromycin, phenytoin, carbamazepin, barbiturater, rifampicin, ciprofloxacin, omeprazol, ranitidin, prikbladet perikon eller proteasomhæmmere).
English: Hypersensitivity to erlotinib or to any of the excipients listed in section 6.1.
Danish: Overfølsomhed over for erlotinib eller over for et eller flere af hjælpestofferne anført i pkt 6.1.
English: Management In case of suspected overdose, Tarceva should be withheld and symptomatic treatment initiated.
Danish: Hvis der er mistanke om overdosering, skal Tarceva seponeres, og symptomatisk behandling påbegyndes.
English: Erlotinib is excreted predominantly as metabolites via the faeces (>90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose.
Danish: Erlotinib udskilles hovedsageligt som metabolitter via fæces (>90 %), og kun en mindre del (ca. 9 %) af en oral dosis udskilles renalt.
English: Erlotinib and smokers
Danish: Elotinib og rygere
English: Table 3: Efficacy results of Tarceva versus chemotherapy in trial ML20650 (EURTAC)
Danish: Tabel 3: Effektresultater for Tarceva versus kemoterapi i studiet ML20650 (EURTAC)
English: • immediately, if you have severe or persistent diarrhoea, nausea, loss of appetite, or vomiting because your doctor may need to interrupt your Tarceva treatment and may need to treat you in the hospital;
Danish: • omgående hvis du får svær eller vedvarende diarré, kvalme, appetittab eller opkastning, fordi din læge måske vil stoppe behandlingen med Tarceva og måske får behov for at behandle dig på hospitalet.
English: Erlotinib is eliminated by hepatic metabolism and biliary excretion.
Danish: Erlotinib udskilles ved hepatisk metabolisme og biliær udskillelse.
English: Tarceva dosing should be interrupted if changes in liver function are severe (see section 4.8).
Danish: Administrationen af Tarceva bør afbrydes ved alvorlige ændringer i leverfunktionen (se pkt.
English: Caution should be exercised when ciprofloxacin or potent CYP1A2 inhibitors (e.g. fluvoxamine) are combined with erlotinib.
Danish: Der skal udvises forsigtighed, når ciprofloxacin eller potente CYP1A2-hæmmere (f.eks. fluvoxamin) kombineres med erlotinib.
English: Co-administration of gemcitabine had no effect on erlotinib plasma clearance.
Danish: Samtidig administration af gemcitabin havde ingen virkning på erlotinibs clearance fra plasma.
English: This study was conducted in Caucasian patients with metastatic or locally advanced NSCLC (stage IIIB and IV) who have not received previous chemotherapy or any systemic antitumour therapy for their advanced disease and who present mutations in the tyrosine kinase domain of the EGFR (exon 19 deletion or exon 21 mutation).
Danish: Dette studie blev udført hos kaukasiske patienter med metastatisk eller lokalt fremskreden NSCLC (stadie IIIB og IV), som ikke tidligere havde fået kemoterapi eller nogen form for systemisk antitumor-behandling for deres fremskredne sygdom, og som havde mutationer i tyrosinkinasedomænet i EGFR (deletion i exon 19 eller mutation i exon 21).
English: Erlotinib and Carboplatin/Paclitaxel
Danish: Erlotinib og carboplatin/paclitaxel
English: Tarceva is available in strengths of 25 mg, 100 mg and 150 mg.
Danish: Tarceva findes i styrkerne 25 mg, 100 mg og 150 mg.
English: No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumours (see section 5.1).
Danish: Der er ikke påvist nogen gavnlig virkning på overlevelse eller andre klinisk relevante virkninger hos patienter med epidermal vækstfaktorreceptor (epidermal growth factor receptor − EGFR)immunhistokemi (Immunohistochemistry - IHC) negative tumorer (se pkt.
English: Patients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist.
Danish: Patienter, som viser tegn og symptomer på keratitis, såsom akut eller forværret: øjeninflammation, tåresekretion, lysfølsomhed, slørret syn, smerter i øjet og/eller røde øjne skal straks henvises til en øjenlæge.
English: The BO25460 (IUNO) study was conducted in 643 patients with advanced NSCLC whose tumors did not harbor an EGFR-activating mutation (exon 19 deletion or exon 21 L858R mutation) and who had not experienced disease progression after four cycles of platinum-based chemotherapy.
Danish: BO25460 (IUNO) studiet blev udført hos 643 patienter med fremskreden ikke-småcellet lungekræft, hvor tumoren ikke havde en EGFR-aktiverende mutation (exon 19 deletion eller exon 21 L858R mutation) og som ikke havde oplevet sygdomsprogression efter fire serier med platin-baseret kemoterapi.
English: What you need to know before you take Tarceva Do not take Tarceva:
Danish: Det skal du vide, før du begynder at tage Tarceva Tag ikke Tarceva
English: In a meta-analysis of NSCLC randomised controlled clinical trials (excluding phase I and single-arm phase II studies due to lack of control groups), the incidence of ILD-like events was 0.9% on Tarceva compared to 0.4% in patients in the control arms.
Danish: I en metaanalyse af NSCLC randomiserede, kontrollerede kliniske studier (fase I og fase II-studier, med en enkelt-arm, blev ekskluderet pga. manglende kontrolgrupper) var forekomsten af ILD-lignende hændelser 0,9% i Tarceva-gruppen sammenlignet med 0,4% i kontrol-gruppen.
English: In some cases your doctor may need to reduce your dose of Tarceva or interrupt treatment:
Danish: I nogle tilfælde vil din læge nedsætte din dosis af Tarceva eller afbryde behandlingen.
English: -Hirsutism -Eyebrow changes -Brittle and Loose nails -Mild skin reactions such as hyperpigmen tation
Danish: - Hirsutisme - Øjenbrynforandringer - Skøre og løse negle - Lette hudreaktioner såsom hyperpigmentering
English: Reported diagnoses in patients suspected of having ILD-like events included pneumonitis, radiation pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, pulmonary fibrosis, Acute Respiratory Distress Syndrome (ARDS), alveolitis, and lung infiltration.
Danish: De rapporterede diagnoser hos patienter med mistanke om ILD-lignende hændelser omfattede pneumonitis, strålepneumonitis, allergisk pneumonitis, interstitiel pneumoni, interstitiel lungesygdom, obliterativ bronkiolitis, pulmonal fibrose, Acute Respiratory Distress Syndrome (ARDS), alveolitis og lungeinfiltrater.
English: When considering the use of Tarceva as a first line or maintenance treatment for locally advanced or metastatic NSCLC, it is important that the EGFR mutation status of a patient is determined.
Danish: Når det overvejes at anvende Tarceva som første linje- eller vedligeholdelsesbehandling for lokal fremskreden eller metastatisk NSCLC er det vigtigt, at en patients EGFR-mutationsstatus er undersøgt.
English: If adverse reactions related to erlotinib are observed, the dose of erlotinib may be reduced.
Danish: Hvis der observeres bivirkninger, der er relateret til erlotinib, kan erlotinibdosis reduceres.
English: Cases of interstitial lung disease (ILD)-like events, including fatalities, have been reported uncommonly in patients receiving Tarceva for treatment of non-small cell lung cancer (NSCLC), pancreatic cancer or other advanced solid tumours.
Danish: I usædvanlige tilfælde er der rapporteret om interstitiel lungesygdom (ILD)-lignende hændelser, inklusive dødsfald, hos patienter, som modtog Tarceva som behandling af ikke-småcellet lungecancer (NSCLC), pancreascancer eller andre fremskredne solide tumorer.
English: Therefore, caution should be used when erlotinib is combined with a potent CYP3A4 inhibitor, e.g. azole antifungals (i.e. ketoconazole, itraconazole, voriconazole), protease inhibitors, erythromycin or clarithromycin.
Danish: Der skal derfor iagttages forsigtighed, når erlotinib kombineres med en potent CYP3A4-hæmmer, f.eks. med antimykotika af azol-gruppen (dvs. ketoconazol, itraconazol og voriconazol), proteasehæmmere, erytromycin eller claritromycin.
English: The efficacy of Tarceva in first-line treatment of patients with EGFR activating mutations in NSCLC was demonstrated in a phase III, randomised, open-label trial (ML20650, EURTAC).
Danish: Virkningen af Tarceva som første-linje-behandling hos patienter med NSCLC med EGFR-aktiverende mutationer blev påvist i et åbent, randomiseret fase III-studie (ML20650, EURTAC).
English: • if you have severe pain in the abdomen, severe blistering or peeling of skin.
Danish: • hvis du har stærke smerter i maven, alvorlig blæredannelse i huden eller afskallende hud.
English: See sections 4.2, 4.4, 4.5, and
Danish: 4.2, 4.4, 4.5 og
English: ADRs occurring in ≥ 10% of patients in BR.21 (treated with Tarceva) and PA.3 (treated with Tarceva plus gemcitabine) studies and ADRs occurring more frequently (≥ 3%) than placebo in BR.21 (treated with Tarceva) and PA.3 (treated with Tarceva plus gemcitabine) studies Tarceva (BR.21) N = 485
Danish: Bivirkninger som forekommer hos ≥ 10 % af patienterne i studie BR.21 (behandlet med Tarceva) og studie PA.3 (behandlet med Tarceva plus gemcitabin) og bivirkninger der forekommer oftere (≥ 3 %) end placebo i studierne BR.21 (behandlet med Tarceva) og PA.3 (behandlet med Tarceva plus gemcitabin)
English: Adequate contraceptive methods should be used during therapy, and for at least 2 weeks after completing therapy.
Danish: Der skal anvendes effektiv kontraception under behandlingen og i mindst 2 uger efter behandlingens afslutning.
English: Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based chemotherapy, or who have prior history of peptic ulceration or diverticular disease are at increased risk.
Danish: Patienter, som samtidig får anti-angiogenetiske lægemidler, kortikosteroider, NSAID og /eller taxanbaseret kemoterapi, eller som tidligere har haft mavesår eller divertikelsygdom, har en forøget risiko.
English: Confounding or contributing factors such as concomitant or prior chemotherapy, prior radiotherapy, pre-existing parenchymal lung disease, metastatic lung disease, or pulmonary infections were frequent.
Danish: Konfunderende eller medvirkende faktorer som f.eks. samtidig eller tidligere kemoterapi, tidligere stråleterapi, præ-eksisterende parenkymatisk lungesygdom, metastatisk lungesygdom eller lungeinfektioner var hyppige.
English: No Grade 4 rash or diarrhoea was observed in either study.
Danish: Der blev ikke observeret udslæt og diarré af grad 4 i disse studier.
English: Based on the mode of action, erlotinib has the potential to be a teratogen.
Danish: På basis af virkningsmekanismen har erlotinib potentialet til at være teratogent.
English: Erlotinib and statins
Danish: Erlotinib og statiner
English: • Infection of hair follicles
Danish: • Betændelse i hårsække
English: • if you have diarrhoea because your doctor may need to treat you with anti-diarrhoeal (for example loperamide);
Danish: Det kan være nødvendigt, at lægen behandler dig med midler mod diarré (f.eks. loperamid).
English: Tarceva contains a sugar called lactose monohydrate.
Danish: Tarceva indeholder en sukkerart, som kaldes lactosemonohydrat.
English: Marketing Authorisation Holder Roche Registration GmbH Emil-Barell-Strasse 1
Danish: Indehaver af markedsføringstilladelsen: Roche Registration GmbH Emil-Barell-Strasse 1
English: In a double-blind, randomised phase III study (MO22162, CURRENTS) comparing two doses of Tarceva (300 mg versus 150 mg) in current smokers (mean of 38 pack years) with locally advanced or metastatic NSCLC in the second-line setting after failure on chemotherapy, the 300 mg dose of Tarceva demonstrated no PFS benefit over the recommended dose (7.00 vs 6.86 weeks, respectively).
Danish: I et dobbeltblindet, randomiseret, fase III-studie (MO22162, CURRENTS), der sammenlignede 2 doser af Tarceva (300 mg mod 150 mg) hos rygere (gennemsnit på 38 pakkeår) med lokalt fremskredent eller metastatisk NSCLC i anden-linje behandling efter svigt af kemoterapi, viste 300 mg Tarceva ingen forbedring på progressionfri overlevelse sammenlignet med den anbefalede dosis (henholdsvis 7,00 mod 6,86 uger).
English: Tarceva resulted in symptom benefits by significantly prolonging time to deterioration in cough, dyspnoea and pain, versus placebo.
Danish: Sammenlignet med placebo medførte Tarceva symptombedring ved signifikant at forlænge tiden indtil forværring af hoste, dyspnø og smerter.
English: The adjusted hazard ratio (HR) for death in the Tarceva group relative to the placebo group was 0.73 (95% CI, 0.60 to 0.87) (p = 0.001).
Danish: Den justerede hazard ratio (HR) for død i Tarceva-gruppen i forhold til placebogruppen var 0,73 (95 % konfidensinterval; 0,60 til 0,87) (p = 0,001).
English: In more severe or persistent cases of diarrhoea, or cases leading to dehydration, particularly in groups of patients with aggravating risk factors (especially concomitant chemotherapy and other medications, symptoms or diseases or other predisposing conditions including advanced age), Tarceva therapy should be interrupted and appropriate measures should be taken to intensively rehydrate the patients intravenously.
Danish: I sværere og mere vedvarende tilfælde af diarré, eller tilfælde, der fører til dehydrering, specielt hos grupper af patienter med forværrede risikofaktorer (især ved samtidig behandling med kemoterapi og andre lægemidler, symptomer eller sygdomme eller andre prædisponerede tilstande herunder høj alder) skal behandlingen med Tarceva afbrydes.
English: In the 45% of patients with known EGFR-expression status, the hazard ratio was 0.68 (95% CI 0.49-0.94) for patients with EGFR-positive tumours and 0.93 (95% CI 0.63-1.36) for patients with EGFR-negative tumours (defined by IHC using EGFR pharmDx kit and defining EGFR-negative as less than 10% tumour cells staining).
Danish: Hazard ratio for patienter med EGFR-positive tumorer var 0,68 (95 % konfidensinterval 0,49-0,94) og 0,93 (95 % konfidensinterval (0,63-1,36) for patienter med EGFR-negative tumorer (defineret ved IHC under anvendelse af EGFR pharmDx kit og definerende EGFR-negativ som farvning af mindre end 10 % af tumorcellerne).
English: Erlotinib potently inhibits the intracellular phosphorylation of EGFR.
Danish: Erlotinib hæmmer effektivt den intracellulære phosphorylering af EGFR.
English: Primary endpoint:
Danish: Primært endepunkt:
English: If the use of antacids is considered necessary during treatment with Tarceva, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva.
Danish: Hvis det er nødvendigt at indtage antacida under behandlingen med Tarceva, bør de tages mindst 4 timer før eller 2 timer efter den daglige Tarceva-dosis.
English: In a clinical study, the concomitant use of erlotinib and rifampicin (600 mg orally once daily for 7 days), a potent CYP3A4 inducer, resulted in a 69% decrease in the median erlotinib AUC.
Danish: I et klinisk studie medførte samtidig anvendelse af erlotinib og rifampicin (600 mg oralt én gang daglig i 7 dage), en potent CYP3A4-induktor, en reduktion på 69 % af den mediane erlotinib AUC.
English: Patients who never smoked had a much greater benefit from erlotinib (survival HR = 0.42, 95% CI 0.28-0.64) compared with current or ex-smokers (HR = 0.87, 95% CI 0.71-1.05).
Danish: Patienter, der aldrig har røget, havde en større virkning af erlotinib (overlevelse HR = 0,42; 95 % konfidensinterval 0,28-0,64) sammenlignet med rygere eller eks-rygere (HR = 0,87; 95 % konfidensinterval 0,71-1,05).
English: After oral administration, erlotinib peak plasma levels are obtained in approximately 4 hours after oral dosing.
Danish: Efter oral administration af erlotinib opnås peak-plasmakoncentrationer efter ca. 4 timer.
English: In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.
Danish: Tarceva er indiceret hos patienter med tumorer uden EGFR-aktiverende mutationer, når andre behandlingsmuligheder vurderes uegnede.
English: Erlotinib and coumarin-derived anticoagulants
Danish: Erlotinib og coumarin-antikoagulantia
English: If the use of ranitidine is considered, it should be used in a staggered manner; i.e. Tarceva must be taken at least 2 hours before or 10 hours after ranitidine dosing.
Danish: Hvis det overvejes at give ranitidin, bør det administreres forskudt; dvs. Tarceva skal administreres mindst 2 timer før eller 10 timer efter ranitidindosering.
English: For the different dose regimens Tarceva is available in strengths of 25 mg, 100 mg or 150 mg.
Danish: Til de forskellige doseringer findes Tarceva i styrker på 25 mg, 100 mg eller 150 mg.
English: In a randomised double-blind study (BR.21; Tarceva administered as second line therapy), rash (75%) and diarrhoea (54%) were the most commonly reported adverse drug reactions (ADRs).
Danish: I et randomiseret dobbeltblindet studie (BR.21: Administration af Tarceva som anden-linje behandling), var udslæt (75 %) og diarré (54 %) de hyppigst rapporterede bivirkninger.
English: • Inflammatory reactions around the fingernail
Danish: • Irritation eller betændelse omkring fingerneglene
English: Diarrhoea and vomiting (very common: may affect more than 1 out of 10 people).
Danish: • Diarré og opkastning (meget almindelig: kan påvirke flere end 1 ud af 10 behandlede).
English: In population pharmacokinetic analysis, increased serum concentrations of total bilirubin were associated with a slower rate of erlotinib clearance.
Danish: I populationsfarmakokinetiske analyser ledsagedes øgede serumkoncentrationer af total bilirubin af en langsommere hastighed af erlotinib-clearance.
English: *** Rash included dermatitis acneiform.
Danish: Udslæt herunder dermatitis acneiformis.
English: When erlotinib was co-administered with ciprofloxacin, a moderate CYP1A2 inhibitor, the erlotinib exposure [AUC] increased significantly by 39%, while no statistically significant change in Cmax was found.
Danish: Når erlotinib blev administreret samtidig med ciprofloxacin, som er en moderat CYP1A2-hæmmer, blev erlotinibeksponeringen [AUC] øget signifikant med 39 %, mens der ikke blev observeret signifikant ændring i Cmax.
English: In the Tarceva plus gemcitabine arm, Grade 3/4 rash and diarrhoea were each reported in 5% of patients.
Danish: I gruppen, som fik Tarceva plus gemcitabin, blev der rapporteret om udslæt og diarré af grad 3/4 hos 5 % af patienterne.
English: Concomitant administration of Tarceva with 300 mg ranitidine, an H2-receptor antagonist, decreased erlotinib exposure [AUC] and maximum concentrations [Cmax] by 33% and 54%, respectively.
Danish: Samtidig administration af Tarceva med 300 mg ranitidin, en H2-receptor-antagonist, nedsatte erlotinibeksponeringen [AUC] og maksimumkoncentrationerne [Cmax] med henholdsvis 33 % og 54 %.
English: In a study of 4 patients (3 with non-small cell lung cancer [NSCLC], and 1 with laryngeal cancer) receiving 150 mg daily oral doses of Tarceva, tumour samples from surgical excisions on Day 9 of treatment revealed tumour concentrations of erlotinib that averaged 1185 ng/g of tissue.
Danish: I et studie hos 4 patienter (3 med ikke-småcellet lungecancer [NSCLC] og 1 med larynxcancer), som fik 150 mg Tarceva dagligt oralt, viste tumorprøver fra kirurgiske ekscisioner på behandlingsdag 9 en samlet gennemsnitlig koncentration af erlotinib i tumorvæv på 1,185 ng/g væv.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Tarceva 25 mg film coated tablets
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Tarceva 25 mg filmovertrukne tabletter
English: Manufacturer Roche Pharma AG Emil-Barell-Strasse 1
Danish: Roche Pharma AG Emil-Barell-Strasse 1
English: However, when Tarceva was dosed in a staggered manner 2 hours before or 10 hours after ranitidine 150 mg b.i.d., erlotinib exposure [AUC] and maximum concentrations [Cmax] decreased only by 15% and 17%, respectively.
Danish: Hvis Tarceva derimod blev administreret forskudt enten 2 timer før eller 10 timer efter 150 mg ranitidin 2 gange daglig, blev erlotinibeksponeringen [AUC] og maksimumkoncentrationerne [Cmax] kun reduceret med henholdsvis 15 % og 17 %.
English: Erlotinib is a substrate for the P-glycoprotein active substance transporter.
Danish: Erlotinib er substrat for P-glykoprotein lægemiddeltransportøren.
English: Patients were randomised 1:1 to receive Tarceva 150 mg daily or up to 4 cycles of platinum based doublet chemotherapy.
Danish: Patienterne blev randomiseret 1:1 til at få Tarceva 150 mg daglig eller op til 4 cyklusser med platinbaseret dublet-kemoterapi.